Medications for Leukemia Acute Lymphoblastic Leukemia All

6 results

  • asparlas

    (calaspargase pegol)
    Servier Pharmaceuticals LLC
    ASPARLAS is indicated for use as part of a multi-agent chemotherapy regimen to treat acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years.

  • leukine

    (SARGRAMOSTIM)
    Partner Therapeutics, Inc.
    LEUKINE is indicated for shortening neutrophil recovery and reducing severe infections in adults with acute myeloid leukemia post-chemotherapy, mobilizing progenitor cells for transplantation, accelerating recovery in bone marrow transplants, treating delayed neutrophil recovery, and increasing survival after acute exposure to myelosuppressive radiation in patients up to 17 years.

  • oncaspar

    (Pegaspargase)
    Servier Pharmaceuticals LLC
    ONCASPAR® is indicated as part of a multi-agent chemotherapy regimen for first-line treatment of acute lymphoblastic leukemia (ALL) in pediatric and adult patients, including those with hypersensitivity to native L-asparaginase.

  • rylaze

    (asparaginase erwinia chrysanthemi (recombinant)-rywn)
    Jazz Pharmaceuticals, Inc.
    RYLAZE is indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients aged 1 month and older who are hypersensitive to E. coli-derived asparaginase, as part of a multi-agent chemotherapy regimen.

  • tecartus

    (brexucabtagene autoleucel)
    Kite Pharma, Inc.
    TECARTUS is an autologous T cell immunotherapy indicated for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL) and B-cell precursor acute lymphoblastic leukemia (ALL). Approval is based on response rates, with further confirmation of clinical benefit required for continued use.

  • xatmep

    (Methotrexate)
    Azurity Pharmaceuticals, Inc.
    XATMEP is indicated for treating pediatric patients with acute lymphoblastic leukemia (ALL) as part of a chemotherapy regimen and managing active polyarticular juvenile idiopathic arthritis (pJIA) in those who respond inadequately or are intolerant to first-line therapies, including NSAIDs.